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Maine AIDS Care
AIDS Consultation Service • Maine Medical Center • Winter 95-96

New Drugs, New Combinations
Show Promise
Four new antiretroviral agents have been approved by the FDA since November
1995. Three of these drugs (saquinavir, indinavir, and ritonavir) represent a potent new class
of antiretroviral agents, the protease inhibitors. The fourth, lamivudine (3TC) is a new reverse
transcriptase inhibitor. In addition, newly released data from 3 different studies docum~nt the
benefits of antiviral combination therapies over zidovudine (AZT) mono therapy . What impact
do these events have on current therapy for HIV?
Benefit of Combination Therapy Supported
On the basis of 3 studies (ACTG 175, Delta I & II), it appears that AZT
monotherapy is no longer the initial treatment of choice in asymptomatic patients.
Combination therapy (AZT & DDI, AZT & DDC) or DDI alone, delayed the onset of AIDS
and improved mortality in asymptomatic patient_s where AZT alone di~ not. Wh~t is_not clear
is what combinations will prove most effective. Of the currently available medication, AZT
& DDI, AZT & DDC, and AZT & 3TC are all of proven efficacy. Others that show promise
include DDI & D4T, and combinations that include protease inhibitors may prove to be the
most effective.
Role of Lamivudine (3TC or Epivir)
Lamivudine, a reverse transcriptase inhibitor, has very limited effectiveness as
monotherapy, but is synergistic with AZT, and appears to inhibit the development of AZTresistance among strains. The combination of AZT and 3TC appears well tolerated and
effective in early clinical trials. Lamivudine has few side effects, although nau~ea ~nd
neuropathy have been infrequently documented. A recent abstract suggests that lam1vudme
may be rarely associated with neutropenia or anemia in patients with low CJ?4 ~ount~.
However, as these patients had late stage HIV and were on an average of 4 medications, 1t
is not certain that lamivudine induced these events.
The combination of AZT, 3TC, and a protease inhibitor (indinavir) were remarkably
potent in a small trial of 26 patients, 24 of whom were rendered aviremic at 6 months.
Continued on Page 2 New Drug:s

First Delavirdine
(U-90) Study Results
Presented
At a recent investigators' meeting in
Washington, DC in January, the initial
results of all 3 protocols for the UpJohn
Delavirdine (DL V) study were presented.
Data for 2,300 patients from all 105 sites
(ACS at MMC is one of the national multicenter study sites) were presented on >400
patients who have~ 1 year in the study.
As a number of Maine patients participated
in this trial we provide a detailed summary
of these results.
Summaty of Results
1. Protocol 0021 (AZT+ DLV or AZT+
Placebo in Patients with CD4 Counts >200
and AZT naive or < 6 Months Prior AZT
Therapy):
Three different doses of
delavirdine were randomized among the
patients receiving the experimental drug
(200mg tid; 300mg tid; & 400mg tid).
Highest blood levels of delavirdine were
seen in the patients receiving 400mg tid.
The best sustained CD4 cell increase was
seen in the patients receiving 300 & 400mg
tid. The HIV RNA viral load was decreased
by 1.0 log with the 400 dose at 4 weeks.
There was an increase in viral load by week
8 to .5 log, but this .5 log overall decrease
was sustained for 60 weeks. Therefore,
UpJohn has made a decision to delete the
200mg arm; the 0021 protocol will be
converting all patients to the 400mg tid
dose. In addition, patients who are receiving
only AZT + placebo or AZT and DL V
200mg or 300mg will be re-randomized to
receive AZT+3TC+placebo or
AZT+3TC+DL V 400mg tid. In addition, a
Phase II (New Trial Design) will be
implemented for approximately 450 patients
in the following way:
AZT+3TC+(DLV placebo)
AZT+3TC+DL V 400mg tid
AZT+DL V 400mg tid+(3TC placebo)

see Delavirdine cont. on page 3

AIDS Conference Offers Reason for Hope
The just completed Third Conference on Retroviruses and Opportunistic I~ections in
Washington, D.C. provided the stage for several new insights regarding the pathophys1ology and
management of HIV disease. A number of promising findings from the past 18 months were
supported or confirmed by new research. Key compo~en~ _offering hope and ex~ite~ent were:
I.
Information on a new class of drug (protease inhibitors) as well as combmabons of drugs
that slow viral replication I regeneration significantly better than the standard
monotherapies of the most recent past. (see New Drug8 page 1)
2.
Information on new tests that measure the actual am01mt of virus in the peripheral system
as well as how the results of these findings can be used to manage treatment.
Antiviral Therapy
Data presented at the conference confirms that treating HIV infection wi~ a combina~on
of antiviral drugs is generally more successful at achieving more complete vrrus suppression,
leading to longer disease-free intervals, increased CD4 cell counts, limiting the emergence of drugresistant viruses, and treating established drug resistance. Combination therapy with selected
reverse transcriptase inhibitors can lead to sustained antiviral efficacy and attenuated viral virulence.
Analysis of survival improvements with combination anti-vital therapy were analyzed from
a number of clinical trial and observational studies (ACTG 175, Delta, Glaxo Wellcome Trial, the
MACS, and the Amsterdam HIV). Although these studies had different designs and were
conducted on different study populations, a broad theme was consistent across studies: 1- Among
ARV-naive patients, initiation of combination antiviral therapy in intennediate stage disease can
provide clinical and survival benefits that are superior to ZDV alone; and 2-. among ~Vexperienced patients, delaying changing therapy until late or very late-stage disease senously
reduces clinical efficacy of combination treatment.
A number of antiretrovirals (nucleoside RT inhibitors, non-nucleoside RT inhibitors,
protease inhibitors, and others) are currently being studied in combinations of 2, 3, or ~ore dru_gs.
Use of measures of viral load, such as branched DNA (bDNA) and RNA polymerase cham reaction
(PCR) assays, combined with studies on drug resistance development, will allow researchers to
rapidly identify the most promising drug combination regimens.
. . .
Data presented using protease inhibitors in combination with several other RT inhib1to~
offered the most exciting combination treatment infonnation to date. Initial data suggests that this
combination will more completely suppress the virus than any antivirals we used in the past. The
prevailing theme at the conference was that protease inhibitors in triple_ combination ~eatme~t (with
2 RT inhibitors) may very well become the standard of care of HIV m the future, influencmg not
only timing of therapy, but other issues like survival time, etc. (See front page article and insert
for more detailed infonnation).
Viral Load Testing Supported
Research data presented in a number of studies indicated that measures of viral load in
the bloodstream are better predictors of an infected persons' future health than any previous
laboratory test or calculation used to make a prognosis. Changes in viral load precede change~ in
CD4 cell count by 1-2 years and accurately predict disease progression. CD4 cell count and viral
load-do not always correlate. For example: a patient can have a high CD4 count and a high viral
load. This patient would have a poorer prognosis than a person who had a high CD4 count a?d
a low viral load. HIV RNA measurements were correlated with clinical endpoints and overall trial
results in a virology substudy in 391 of the 2467 patients enrolled in ACTG 175. A tenfold (I-log)
increase in viral load resulted in a 3.83 fold (aggregate endpoint) increased risk of AIDS, death,
or 50% decline in CD4 cell counts, a 5.77-fold increase in risk of AIDS or death, and a 6.0 - fold
increase in risk of death.
It was noted that plasma HIV RNA measurements will be useful for patient management (with 2
gathered 2 wks to I month apart to establish a baseline). However, the proportion of tream:ient
effect explained by change in viral load has not yet been defmed. A general theme ~t van~us
presentations in the conference was that viral load needs to be decreased as much as possible, with
a goal being to get a patient to <10,000 copies/ml or even aviremic.Several investigators sounded
a note of caution that viral burden in the blood may not reflect viral pathogenesis throughout the
body. In particular, since lymph nodes have been identified as the p~ciple site_ of viral replicati~n
for much of the disease course, investigators have continued to examme HIV m lymph nodes via
biopsies, and compared viral loads with plasma HIV RNA levels. Results have varied, with several
studies reporting no parallel lymph node responses or slower viral clearance from nodes. Further
study is needed in this area.

New Drugs, cont.
Protease Inhibitors Spark Excitement
Protease inhibitors, a new class of antiretroviral
drug that act to prevent the fonnation of
infectious virions at a point in viral assembly
appear to present a very promising advance in
antiretroviral treatment. Saquinavir, the first
protease inhibitor to be released, has been on
the market for several months. Two additional
protease inhibitors, indinavir (Merck) and
ritonavir (Abbot) were approved by the FDA
on March I, 1996. These drugs appear to be
additive or synergistic when combined with
reverse transcriptase inhibitors, and based on
their effect on HIV plasma RNA levels, appear
to be more potent than reverse transcriptase
inhibitors. Resistance to protease inhibitors
does not overlap with known genotypic
resistance to RT inhibitors, and their toxicities
are not overlapping. In fact, toxicity to
protease inhibitors has been minimal, limited to
mild GI intolerance, circumoral paresthesias,
nephrolithiasis, and dysgeusia, and mild
elevation in transaminase and triglyceride
levels.
So what should be our strategy now that these
drugs are becoming available? Guidelines do
not yet exist. Preliminary data suggests that
ritonavir and indinavir are the most potent
protease inhibitors.
Ritonavir decreased
mortality and onset of opportunist infections by
1/2 in a group of over 1,000 late stage patients.
Indinavir, when combined with AZT+3TC,
rendered 24 of 26 patients aviremic when
plasma RNA was measured. It is reasonable to
believe that very low plasma HIV RNA levels
will be associated with delayed disease
progression.
Therefore, these preliminary
results have sparked excitement among
clinicians caring for person, with HIV.
Where does this infonnation leave us
at this point? For now, initiation of therapy is
still usually begun in patients with CD4 counts
of <500, with the exception that some
clinicians now favor treating patients with
higher CD4 counts if they have a high viral
load documented on 2 or more occasions.
Secondly, recent data suggests that when
therapy is initiated, combination therapy
(AZT+DDI or AZT+DDC) is probably
preferable to monotherapy. Based on the
results of ACTG 175, monotherapy with DDI
would be an acceptable alternative. The use of
3TC with AZT appears to be another option
that is well tolerated. Whether or not to add
the new protease inhibitors early in therapy, or
to reserve them for patients when other
therapies fail to suppress viral load or to
stabilize CD4 counts, is an open question. In
general, toxicity of these agents appears to be
low, but data on their interactions with other
commonly used drugs in HIV is still sparse.

Principles of Protease Inhibitor Use
1.

Start with highest appropriate dose and avoid dose adjustment if possible.

2.

Use in combination with other agents.

3.

Be aware of drug interactions (see other side of insert).

New Antiviral Agents & Combinations
Class

Drug

Usual Dosage

Side Effects

Effective Regimens

RT Inhibitors
Nucleoside

[Non-Nucleoside

AZT
(Zidovudine)

200 mgtid

Bone marrow suppression AZT
Myopathy
AZT+DDI
AZT+DDC
GI symptoms
AZT+3TC
All regimens with or without
a protease inhibitor.

DOI
(didanosine)

200mgbid

Pancreatitis
GI intolerance
Neuropathy

DOI
DDI+AZT
DOI + D4T (Z?)
All regimens with or without
a protease inhibitor.

DOC
(deoxycytidine)

0.75 mg tid

Pancreatitis (rare)
Neuropathy
Oral I esophageal ulcers

DOC
DDC+AZT
All regimens with or without
a protease inhibitor.

D4T
(Stavudine)

40 mg bid

Neuropathy

D4T
D4T+DDI(?)

3TC
(Lamivudine)

150 mg bid

GI intolerance
Neutropenia (rare)

3TC+AZT
AZT + 3TC + Protease
Inhibitor

Delavirdine
(available through
compassionate use
only)

400 mgtid

Rash
GI intolerance

Delavirdine + AZT
Delavirdine + DOI
Delavirdine + AZT + DOI
or DOC

Saquinavir

600 mg bid
(with food)

GI intolerance
Drug interactions

Saquinavir + 1 or 2 RT
inhibitors

Ritonavir

600 mgtid
(with food)

GI intolerance
Drug interactions

Ritonavir + 1 or 2 RT
inhibitors

lndinavir

800 mg tid
(with food)

GI intolerance
Nephrolithiasis (2-5%)
Drug interactions

AZT + 3TC + lndinavir
Indinavir + 1 or 2 RT
inhibitors

Protease Inhibitors

Potential Drug Interactions - Ritonavir
(Data on lndinavir Not Available)

Avoid
meperidine (Demoral)
piroxicam (Feldene)
propoxyphene (Darvon)
amiodarone (Cordarone)
encainide (Enkaid)
flecainide (Tambocor)
propafenone (Rythmol)
quinidine
rifabutin (Mycobutin)

Analgesic

Cardiovascular
(Antiarrhythmic)

Antimycobacterial

Alternative Treatment
acetaminophen (Tylenol)
..
aspmn
oxycodone (Percodan)

clarithromycin (Biaxin)
ethambutol (Myambutol)

Cardiovascular
(calcium channel blocker)

bepridil (Vascor)

Cold & Allergy
(antihistamine)

astemizole (Hismanal)
terfenadine (Seldane)

Gastrointestinal

cisapride (Propulsid)

Psychotropic
(antidepressant)

bupropion (Wellbutrin)

fluoxetine (Prozac)
desipramine (Norpramin)

Psychotropic
(sedative/hypnotic)

alprazolam (Xanax)
clorazepate (Tranxene)
diazepam (Valium)
estazolam (Prosam)
fluroepam (Dalmane)
midazolam (Versed)
triazolam (Halcion)
zolpidem (Ambien)

temazepam (Restoril)
lorazepam (Ativan)

loratadine (Claritin)

Ifyou have questions regarding the use or
side effects of Protease Inhibitors call the
AIDS Consultation Service
Treatment Information Line @
1-800-871-2701

HIV Patient Assistance Programs
Encouragement over new drug therapies for persons with HIV is often met with frustration
when faced with the financial cost. It can be overwhelming for people to figure out on their own
how to access medication assistance programs, when and how to apply for Medicaid, and what they
will be expected to pay for themselves. A person with HIV or AIDS could easily deplete a lifetime
of savings just in paying for medications. People with HIV/AIDS benefit from having their own
case manager or social worker to assist them in accessing whatever assistance they are entitled to.
Most private insurers offer prescription drug coverage that includes coverage for
HIVI AIDS drugs. A person who has Medicaid coverage will qualify for medication assistance with
any FDA approved drug. The Maine Dept of Human Services' Drug Reimbursement Program (207287-5060) provides reimbursement for some medication for patients with HIV who meet financial
requirements and have no other way to pay for prescriptions, or are pending Medicaid coverage or
reimbursement by an insurance plan. Drugs covered under this program include: Pentamidine,
AZT, DDI, DDC, D4T, Acyclovir, Fluconazol, and Bactrim.
Following is a list of the pharmaceutical companies who offer HIV patient assistance
programs for some of the newer medications mentioned in this newsletter.
These pharmaceutical companies will supply patients with drug if they meet income guidelines and
are not eligible for or have exhausted Medicare, Medicaid, Ryan White Funds, and all other third
party coverage. Applications must be completed by a physician with DEA number.

Epivir (JTC), AZT, Acyclovir
Glaxo Wellcome Co., Patient Assistance Program
PO Box 52035
Phoenix, AZ 85072
l -800-513-3028

lnvirase (Squinavir), DDC,
Roche HIV Therapy Assistance Program
340 Kingsland Street
Nutley, NJ 07110
l-800-282-7780

D4T (Stavudine), DDI
Bristol Meyers Squibb
Patient Assistance Program
1800 Robert Fulton Drive
Raston, VA 22091
l-800-272-4878

Crixivan (lnidinavir)
Merck Pharmaceutical Co.
Patient Assistance Program
PO Box 4 (WP35-258)
West Point, PA 19468-0004
l-800-672-6372

Norvir (Ritonavir)
Abbott Pharmaceutical Co.
Patient Assistance Program
l-800-688-9118

Community Counseling Center's New
AIDS Family Therapy Initiate
Helps Persons with HIV and Their Families
Community Counseling Center's AIDS Family Therapy Initiative is a new, comprehensive family
treatment program for Cumberland County residents who have been affected by the HIV/AIDS
virus. This program includes family members, friends, and caregivers. The Initiative is designed
to help individuals and their families deal with the many implications of HIV disease.
Families affected by HIV frequently handle very difficult issues such as loss and impending loss,
the unpredictability of the disease, and the sometimes extraordinary demands of providing physical
and emotional care for persons with HIV. Through this program, individual and group therapy is
provided in a safe, supportive environment in which each family member can communicate, express
feelings, and develop helpful ways of dealing with stress.
Any family member or friend who is part of a person with HIV/AIDS caregiving support network
can participate in the program (the persons with HIV/AIDS does not have to live in Cumberland
County). For more information, contact the AIDS Family Therapy Initiative Coordinator at
Community Counseling Center, (207) 874-1030. Community Counseling Center is a United Way
agency.

Delavirdine cont.
The general consensus is that DL V
used in combination with AZT provides an
effective and sustained decrease in viral load
(.5 log) and a smaller but sustained increase in
CD4 cell count (20-30 cells). The AIDS
Consultation Service has patients who have
been enrolled in this study for almost 2 years
now. We · are pleased to see that the initial
results demonstrate a benefit of delavirdine
therapy.
2. DDI + placebo vs. DDI + DLV 400mg
tid: Preliminary results of this arm showed
that DL V in combination with DDI decreased
viral load initially .8-.9 log (vs. DDI to .4 log
alone), with a .5 log sustained decrease x60
weeks. ·There was a sustained CD4 cell count
increase of 10-25 cells above baseline at 60
weeks. However, although these results give
evidence that the combination of DL V+DDI
does suppress viral replication, it appears that
this is so because AZT seems to delay
resistance to DL V and vice versa.
No changes are planned in the this
protocol at this time.
3. Protocol #23 Salvage Protocol: DLV
400mg tid + AZT 300 mg + DDI or DDC Triple Combination Treatment: The results
of this arm of the study (with data available on
200 patients) showed that the great majority of
these patients were AZT experienced for l-3
years, and DDI experienced for 3-24 months.
patients could roll over into this protocol only
if they had a 50% decrease in CD4 cells, an
AIDS defining illness, or upon trial completion.
The results showed that DL V works in triple
combination therapy, with the strongest
combination being DL V+AZT+DDI. These
Patients had a l 0-40 cell increase in CD4 cell
counts and a 0.3-0.8 log decrease in viral RNA
for ~ 24 weeks. It was also concluded that it
is best to switch to 2 new drugs when going to
triple combination therapy; the effect on CD4
and viral load is greater with 2 new drugs.
The DL V study provides the largest data base
to date for HIV RNA PCR and bDNA viral
load results. We look forward to further data
analysis. Please note DL V is now available in
Open Label by contacting UpJohn Pharmacia
Co.

World AIDS Cases
U.S. AIDS Cases
U.S. AIDS Deaths

4,500,000*
501,310
311,381

Reported through 10/31/95 by CDC

Maine AIDS Cases
Maine AIDS Deaths

712
335

As reported through December 31, 1995

Upcoming HIV/AIDS Educational Sessions
April 23, 1996 Primary Care Management of HIV & Living with HIV
Central Maine Medical Center, Lewiston Maine
9:00 am - 12:00 pm
Sandra Putnam, RN, MSN, FNP Nurse Coordinator, AIDS Consultation Service
May 29, 1996

AIDS Consultation Service - HIV/AIDS Symposium
Maine Medical Center, Portland Maine
8:00 am - 4:00 pm
Topics & Speakers Include:
New Concepts in HIV and New Approaches to Antiviral Treatment
Dr. Scott Hammer - New England Deaconess Hospital
Primary Care Management - Applying the Newest Science to Disease Management
Dr. Harvey Makadon - Beth Israel Hospital
Opportunistic Infection Management
Dr. Howard Heller - Mass General
Afternoon Breakout Clinical Tracks Include:
1.
Pain Control, Depression, & Dementia - Challenges to Management in HIV
2.
HIV in Women
3.
HIV Update for People Living with AIDS - Answering All Your Questions
(Panel presentation I discussion)

Maine Medical Center's
AIDS Consultation Service
22 Bramhall Street
Portland Maine 04102
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